SCHEMBL20190681

SCHEMBL20190681

O=[N+]([O-])c1cnccc1OC(F)C(F)F

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.41
ALDH1A1 P00352 5/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 7/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
MAPK1 P28482 1/20 0.34
CHUK O15111 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6117681 0.81 PDK1 (0.47) HTTALDH1A1RAB9AMAPTLMNA
SCHEMBL16703853 0.77 HTT (0.40) HTTALDH1A1RAB9AMAPTLMNA
SCHEMBL29135344 0.77 ALDH1A1 (0.55) HTTALDH1A1RAB9AMAPTLMNA
SCHEMBL187850 0.75 ALDH1A1 (0.56) HTTALDH1A1RAB9AGAAKMT2A
SCHEMBL8567061 0.74 MAPT (0.42) HTTALDH1A1RAB9AMAPTLMNA
SCHEMBL11021559 0.74 HTT (0.36) HTTALDH1A1RAB9AMAPTLMNA
Hydrochloric Acid SCHEMBL3601018 0.73 ALDH1A1 (0.55) HTTALDH1A1RAB9AGAAKMT2A
SCHEMBL31342915 0.73 MEN1 (0.51) HTTALDH1A1RAB9AMAPTLMNA
SCHEMBL26833769 0.73 MEN1 (0.51) HTTALDH1A1RAB9AMAPTLMNA
SCHEMBL29226251 0.72 S100A4 (0.40) ALDH1A1RAB9AMAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110545817-B GSK-3 inhibitors 百时美施贵宝公司 2022-11-15 CN disclosed
CN-110225912-B GSK-3 inhibitors 百时美施贵宝公司 2022-10-21 CN disclosed
EP-3544980-A1 GSK-3 INHIBITORS Bristol-Myers Squibb Company (US) 2019-10-02 EP disclosed
WO-2018098411-A1 GSK-3 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-31 WO disclosed